Vol. 21/No. 24 | OncologyLive

Expert Sees Need for Better Guideline Adherence in NSCLC

January 19, 2021

At the beginning of his career as a medical oncologist in the 1990s, lung cancer specialist Rogerio C. Lilenbaum, MD, was squarely focused on diagnosing and treating his patients while translating emerging clinical research into practice.

Pandemic Inspires New Outreach Program

January 19, 2021

As oncologists, we are here to help patients and their families as much as we can. That is why we went into cancer medicine. It is what we do every day. Until the coronavirus disease 2019 pandemic knocked on our doors.

Markman: COVID-19 Takes Science on a Roller-Coaster Ride

January 10, 2021

From the Editor

In a pandemic, the public and its leaders yearn for relatively simple answers that can lead to solutions and forceful actions such as preventing serious infection and hospitalizations, treating active illness, and developing safe and effective vaccines quickly made available to the public.

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

January 08, 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

Next-Generation Cytotoxic Therapy Moves Forward in mCRPC

January 07, 2021

VERU-111, a next-generation form of chemotherapy, has shown promising signs of efficacy as a treatment option for men with metastatic castration-resistant prostate cancer whose disease has progressed while receiving androgen receptor–targeting therapy.